MAPT and Alzheimer disease: Even for the NfL, NT1 and FL-tau assays, many AD and control plasmas, which, when unmanipulated, had readily measurable values (Supplemental Figure S4), did not yield detectable signals when treated with GuHCl (Figure 3).